The relationship between ABO blood group type and tumor grade,stage,recurrence and progression in transitional cell carcinoma of the bladder: A preliminary report

Abstract

Objectives:

ABO blood grouping is a well-proven prognostic factor in many malignancies. This study aims to study the association and impact of ABO blood group on disease recurrence and progression in bladder carcinoma.

Material and methods:

Patients with bladder carcinoma undergoing transurethral resection of bladder tumor (TURBT) were studied prospectively for at least 1-year follow-up for recurrence and progression of the disease. Demographic profile along with blood group was noted.

Results:

Two hundred patients were included in the study and 194 patients were included in the final analysis. Muscle-invasive bladder cancer was present in 39 (20.1%) patients and the high-grade tumor was present in 88 (45.3%) patients. There was no statistical significance between the association of blood grouping and grade (p=0.29) and stage of the disease (p=0.20). During the follow-up period, there were 100 (64.5%) recurrences and 15 (9.7%) patients with non-muscle-invasive bladder carcinoma had progression. The association of blood group with recurrence (p=0.66) and progression (p=0.11) of disease was not statistically significant.

Conclusion:

There is no association between bladder cancer and ABO blood group in terms of grade and stage of the disease. The recurrence and progression of the disease did not differ significantly in different blood groups.

Level of Evidence:

Keywords

Bladder carcinoma blood group progression recurrence

Get full access to this article

View all access options for this article.

References

Fereley

Shin

Bray

et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893–2917.

Siegel

Naishadham

Jamal

Cancer statistics 2013. CA Cancer J Clin 2013; 63: 11.

Orlow

Lianes

Lacombe

et al. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 1994; 54: 2848–2851.

Klatte

Xylinas

Rieken

et al. Impact of ABO blood type on outcomes in patients with primary non muscle invasive bladder cancer. J Urol 2014; 191: 1238–1243.

Chandra

Gupta

Frequency of ABO and rhesus blood groups in blood donors. Asian J Transfus Sci 2012; 6: 52–53.

Sobin

Gospodarwicz

Witterkind

TNM classification of malignant tumors. UICC International Union Against Cancer 7th ed. NJUSA: Wiley-Blackwell, 2009, pp.262–265.

Babjuk

Burger

Zigeuner

et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013; 64: 639.

Hoskins

Loux

Britten

et al. Distribution of ABO blood groups in patients with pernicious anemia, gastric carcinoma and gastric carcinoma associated with pernicious anemia. N Engl J Med 1965; 273: 633–637.

Aird

Lee

Roberts

JA.

ABO blood groups and cancer of oesophagus, cancer of pancreas, and pituitary adenoma. Br Med J 1960; 1: 1163–1166.

10.

Reid

Mohandas

Red blood cell blood group antigens: structure and function. Semin Hematol 2004; 41: 93–117.

11.

Orntoft

Meldgaard

Pedersen

et al. The blood group ABO gene transcript is down regulated in human bladder tumors and growth-stimulated urothelial cell lines. Cancer Res 1996; 56: 1031.

12.

Llopis

Ruiz

Server

et al. ABO blood groups and bladder carcinoma. Eur Urol 1990; 17: 289–292.

13.

Raitanen

Tammela

TL.

Relationship between blood groups and tumor grade, number, size, stage, recurrence and survival in patient with transitional cell carcinoma of the bladder. Scand J Uro Nephrol 1993; 27: 343–347.

14.

Süer

Özcan

Gökçe

et al. Do blood groups have effect on prognosis of patients undergoing radical cystectomy? Int Urol Nephrol 2014; 46: 15–21.

15.

Engel

Soave

Peine

et al. The impact of the ABO and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World J Urol 2015; 33: 1769–1776.

16.

Pellucchi

Freschi

Ibrahim

et al. Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. J Urol 2011; 186: 2194–2199.